Ventures

XtRNA Bio is developing a pioneering gene therapy to treat Charcot Marie Tooth (CMT) disease type 2D, leveraging tRNA supplementation therapies. Their patented treatment targets mutations in tRNA synthetases, offering a new therapeutic modality with vast potential for various diseases. They are raising €5M to develop a clinical candidate for CMT2D and expand their pipeline. CMT, a hereditary and heterogeneous disease, affects 1 in 2500 people worldwide, causing progressive muscle wasting, loss of sensation, and chronic pain, with no current cure.

Haermonics addresses the challenge of complications after open heart surgery with a transformative solution. Excessive blood loss and clots post-surgery lead to numerous issues, including reoperations and cardiac tamponades, resulting in significant healthcare costs and loss of lives. The Haermonics Flush device offers a preventive approach by flushing the pericardial cavity after surgery, limiting blood loss and clot formation. By providing medical professionals with better patient status monitoring, Haermonics Flush empowers doctors to make more informed decisions, ultimately saving thousands of lives and billions in hospital costs.

Audaxis Medical revolutionizes the treatment of stress urinary incontinence with Plielle™, a next-generation polyurethane support system. While traditional polypropylene slings often lead to chronic inflammation and tissue complications, Plielle™ offers a safer alternative by replicating the native structure and viscoelastic properties of the pelvic floor. By providing a high-performance, biocompatible solution that integrates seamlessly with human tissue, Audaxis aims to improve clinical outcomes and restore patient confidence, filling a critical gap in women’s healthcare.

Flash Pathology revolutionizes tissue assessment with its scanner, with immediate imaging of biopsy and surgical specimens in the moment of operation. Unlike traditional methods, taking hours and requiring extensive labor, the Flash Pathology scanner visualizes cell structures within seconds without any preparation. This, non-labor-intensive solution enables distinguishing healthy tissue from tumors in real-time, reducing the need for revision surgeries and unnecessary biopsies.

AIDO enhances precision control during endoscopic procedures with its drive unit. Physicians can now maintain control of the endoscope shaft while operating tools, saving time and improving efficiency. This platform technology streamlines the control of instruments inserted through the endoscope's working channel, offering automatic insertion and precise control, ultimately improving patient safety and procedural outcomes.

Lumabs introduces a revolutionary diagnostic platform offering quick and precise biomolecule measurement right at the point of care. By eliminating the need for time-consuming laboratory processes, such as ELISA tests, Lumabs ensures patients receive vital diagnostic results immediately. This innovation is crucial in emergency and intensive care settings, where real-time information can guide rapid treatment decisions, potentially saving lives.

Rheumasense combines LC-MS biomarker testing with advanced machine learning to provide real-time, objective insights into rheumatoid arthritis (RA) disease activity. Our technology measures specific metabolites linked to RA progression, offering accurate, quantitative data for timely, personalized treatment adjustments. With a simple at-home blood collection kit and clinically validated testing at Mayo Clinic Laboratories, we deliver actionable results quickly and cost-effectively, improving patient outcomes and supporting proactive care.

Epilepsy causes uncontrolled seizures, greatly reducing quality of life and sometimes leading to early death. Over 50 million people worldwide have epilepsy, but only two-thirds respond to medication. For those with drug-resistant epilepsy, treatment options are limited and often ineffective. MIR Therapeutics is developing a new gene therapy to provide lasting and powerful seizure control for drug-resistant epilepsy patients. Their therapy delivers microRNA-335 to the affected brain regions using an AAV9 viral vector, which helps control hyperexcitability by regulating voltage-gated sodium channels. This results in fewer and less severe seizures.